samedan logo
 
 
spacer
home > ict > spring 2017 > getting better
PUBLICATIONS
International Clinical Trials

Getting Better

Charlton Ogburn Jr, an American journalist and author, wrote “perhaps because we are so good at organizing, we tend as a nation to meet any new situation by reorganizing; and a wonderful method it can be for creating the illusion of progress while producing confusion, inefficiency and demoralization”. I edited the first edition of European Pharmaceutical Contractor in November 1996 and now, 20 years later, I look back and wonder if the following industry changes have done more than create the illusion of progress:
  • Increased size, duration and cost of trials
  • IT and communication
  • Data protection and production
  • The advent of ‘technology’ leading to vastly more data, more regulation and legislation, and increased patient and investigator involvement
  • Size, development and financial basis of CROs
  • Types of outsourcing and its contracts

Some things have not changed, however, such as time and overall success rate from discovery to marketing; the number and speed of withdrawal of ‘unsuitable’ drugs; and the amount of trials that are delayed or aborted.

We can perhaps define progress as whether medicines are being developed faster, cheaper or better.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

spacer
Dr Graham Hughes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical trials in the post Brexit Europe

While negotiations are still ongoing, the structure of the post-Brexit medicine testing and approval process is still unclear, and the UK government has so far ruled out an extension to the transition period which is due to come to an end at the end of this year.
More info >>

White Papers

Comparator Sourcing in Oncology Trials

Clinical Services International

This is an exciting time for oncology trials, year on year record numbers of therapeutics are launched and the indications for many drugs on the market are increasing rapidly. Immunotherapies and next generation biotherapeutics are being approved for more tumour types and a growing percentage of the late stage oncology pipeline are targeted biologics.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement